Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice
Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic...
Gespeichert in:
Veröffentlicht in: | Actas urologicas españolas 2013-06, Vol.37 (6), p.330-337 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng ; spa |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 337 |
---|---|
container_issue | 6 |
container_start_page | 330 |
container_title | Actas urologicas españolas |
container_volume | 37 |
creator | Esteban, M Castro, D M |
description | Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out.
Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention.
We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment. |
doi_str_mv | 10.1016/j.acuro.2012.05.007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1445912824</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1445912824</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-9f920ff143ec917075ce68f639431806b96fb2eb5c9f8250e18bbcfcffe581a33</originalsourceid><addsrcrecordid>eNo1kE9LxDAUxIMg7rr6CQTJ0UtrkjZt4k3Ef7CgBz0vafZFsyRNTVJ0v73ddT09mDfzgxmELigpKaHN9aZUeoyhZISykvCSkPYIzWkjZdFKQWboNKUNIayuRHuCZoxJLjlt5ujn9VNFr3Rw4cNq5XCOoLKHPuNgsAvfEPEYba_idnopnXHa-iEHn7Dt8eS7wdYPDnYJlW3od7EIOvhJWe-VvVM72-_5ww5iNZyhY6NcgvPDXaD3h_u3u6di-fL4fHe7LAZa01xIIxkxhtYVaElb0nINjTBNJeuKCtJ0sjEdg45raQTjBKjoOm20McAFVVW1QFd_3CGGrxFSXnmbNDineghjWtG65pIyMU2zQJcH69h5WK-GaP3Ue_W_VvULfaBvHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1445912824</pqid></control><display><type>article</type><title>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Esteban, M ; Castro, D M</creator><creatorcontrib>Esteban, M ; Castro, D M ; comité científico</creatorcontrib><description>Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out.
Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention.
We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.</description><identifier>EISSN: 1699-7980</identifier><identifier>DOI: 10.1016/j.acuro.2012.05.007</identifier><identifier>PMID: 22959516</identifier><language>eng ; spa</language><publisher>Spain</publisher><subject>5-alpha Reductase Inhibitors - adverse effects ; 5-alpha Reductase Inhibitors - therapeutic use ; Adrenergic alpha-Antagonists - adverse effects ; Adrenergic alpha-Antagonists - therapeutic use ; Algorithms ; Deamino Arginine Vasopressin - adverse effects ; Deamino Arginine Vasopressin - therapeutic use ; Drug Interactions ; Drug Therapy, Combination ; Humans ; Hyponatremia - chemically induced ; Lower Urinary Tract Symptoms - classification ; Lower Urinary Tract Symptoms - diagnosis ; Lower Urinary Tract Symptoms - drug therapy ; Male ; Muscarinic Antagonists - adverse effects ; Muscarinic Antagonists - therapeutic use ; Prostatism - diagnosis ; Prostatism - drug therapy ; Prostatism - surgery ; Severity of Illness Index ; Sodium Potassium Chloride Symporter Inhibitors - adverse effects ; Sodium Potassium Chloride Symporter Inhibitors - therapeutic use ; Urinary Retention - chemically induced</subject><ispartof>Actas urologicas españolas, 2013-06, Vol.37 (6), p.330-337</ispartof><rights>Copyright © 2012 AEU. Published by Elsevier Espana. All rights reserved.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,776,780,785,786,23909,23910,25118,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22959516$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Esteban, M</creatorcontrib><creatorcontrib>Castro, D M</creatorcontrib><creatorcontrib>comité científico</creatorcontrib><title>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</title><title>Actas urologicas españolas</title><addtitle>Actas Urol Esp</addtitle><description>Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out.
Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention.
We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.</description><subject>5-alpha Reductase Inhibitors - adverse effects</subject><subject>5-alpha Reductase Inhibitors - therapeutic use</subject><subject>Adrenergic alpha-Antagonists - adverse effects</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Algorithms</subject><subject>Deamino Arginine Vasopressin - adverse effects</subject><subject>Deamino Arginine Vasopressin - therapeutic use</subject><subject>Drug Interactions</subject><subject>Drug Therapy, Combination</subject><subject>Humans</subject><subject>Hyponatremia - chemically induced</subject><subject>Lower Urinary Tract Symptoms - classification</subject><subject>Lower Urinary Tract Symptoms - diagnosis</subject><subject>Lower Urinary Tract Symptoms - drug therapy</subject><subject>Male</subject><subject>Muscarinic Antagonists - adverse effects</subject><subject>Muscarinic Antagonists - therapeutic use</subject><subject>Prostatism - diagnosis</subject><subject>Prostatism - drug therapy</subject><subject>Prostatism - surgery</subject><subject>Severity of Illness Index</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - adverse effects</subject><subject>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Urinary Retention - chemically induced</subject><issn>1699-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE9LxDAUxIMg7rr6CQTJ0UtrkjZt4k3Ef7CgBz0vafZFsyRNTVJ0v73ddT09mDfzgxmELigpKaHN9aZUeoyhZISykvCSkPYIzWkjZdFKQWboNKUNIayuRHuCZoxJLjlt5ujn9VNFr3Rw4cNq5XCOoLKHPuNgsAvfEPEYba_idnopnXHa-iEHn7Dt8eS7wdYPDnYJlW3od7EIOvhJWe-VvVM72-_5ww5iNZyhY6NcgvPDXaD3h_u3u6di-fL4fHe7LAZa01xIIxkxhtYVaElb0nINjTBNJeuKCtJ0sjEdg45raQTjBKjoOm20McAFVVW1QFd_3CGGrxFSXnmbNDineghjWtG65pIyMU2zQJcH69h5WK-GaP3Ue_W_VvULfaBvHw</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Esteban, M</creator><creator>Castro, D M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201306</creationdate><title>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</title><author>Esteban, M ; Castro, D M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-9f920ff143ec917075ce68f639431806b96fb2eb5c9f8250e18bbcfcffe581a33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2013</creationdate><topic>5-alpha Reductase Inhibitors - adverse effects</topic><topic>5-alpha Reductase Inhibitors - therapeutic use</topic><topic>Adrenergic alpha-Antagonists - adverse effects</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Algorithms</topic><topic>Deamino Arginine Vasopressin - adverse effects</topic><topic>Deamino Arginine Vasopressin - therapeutic use</topic><topic>Drug Interactions</topic><topic>Drug Therapy, Combination</topic><topic>Humans</topic><topic>Hyponatremia - chemically induced</topic><topic>Lower Urinary Tract Symptoms - classification</topic><topic>Lower Urinary Tract Symptoms - diagnosis</topic><topic>Lower Urinary Tract Symptoms - drug therapy</topic><topic>Male</topic><topic>Muscarinic Antagonists - adverse effects</topic><topic>Muscarinic Antagonists - therapeutic use</topic><topic>Prostatism - diagnosis</topic><topic>Prostatism - drug therapy</topic><topic>Prostatism - surgery</topic><topic>Severity of Illness Index</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - adverse effects</topic><topic>Sodium Potassium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Urinary Retention - chemically induced</topic><toplevel>online_resources</toplevel><creatorcontrib>Esteban, M</creatorcontrib><creatorcontrib>Castro, D M</creatorcontrib><creatorcontrib>comité científico</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Actas urologicas españolas</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Esteban, M</au><au>Castro, D M</au><aucorp>comité científico</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice</atitle><jtitle>Actas urologicas españolas</jtitle><addtitle>Actas Urol Esp</addtitle><date>2013-06</date><risdate>2013</risdate><volume>37</volume><issue>6</issue><spage>330</spage><epage>337</epage><pages>330-337</pages><eissn>1699-7980</eissn><abstract>Introducing a consensus on pharmacological treatment of male LUTs to be applied to Urology Primary Care. EVIDENCE COMPILATION: The consensus has been created by an expert committee based on the latest recommendations by the European and American Guides for male LUTs treatment. Also, a bibliographic review of the latest advances in the therapeutical approach to these patients has been carried out.
Although the prevalence of both LUTs and overactive bladder is high, and its impact on the quality of life and social cost have been widely described, the number of patients treated is low. On the other hand, current clinical practice doesn't necessarily match the Guides and for this reason false perceptions of the available treatments circulate. For instance, men with storage LUTS are often treated inadequately with α-blockers or 5-α-reductase inhibitors due to underlying obstructive disorders. However, it is known that the incidence of real obstruction tends to be low. Current evidence, though limited, shows that antimuscarinic drugs may be used safely by men with LUTs, and are not associated with an increase in the prevalence of high urinary retention.
We propose an algorithm for the management of male LUTs in which various levels of clinical evaluation are shown for a specific diagnose, as well as for choosing the most appropriate treatment.</abstract><cop>Spain</cop><pmid>22959516</pmid><doi>10.1016/j.acuro.2012.05.007</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1699-7980 |
ispartof | Actas urologicas españolas, 2013-06, Vol.37 (6), p.330-337 |
issn | 1699-7980 |
language | eng ; spa |
recordid | cdi_proquest_miscellaneous_1445912824 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | 5-alpha Reductase Inhibitors - adverse effects 5-alpha Reductase Inhibitors - therapeutic use Adrenergic alpha-Antagonists - adverse effects Adrenergic alpha-Antagonists - therapeutic use Algorithms Deamino Arginine Vasopressin - adverse effects Deamino Arginine Vasopressin - therapeutic use Drug Interactions Drug Therapy, Combination Humans Hyponatremia - chemically induced Lower Urinary Tract Symptoms - classification Lower Urinary Tract Symptoms - diagnosis Lower Urinary Tract Symptoms - drug therapy Male Muscarinic Antagonists - adverse effects Muscarinic Antagonists - therapeutic use Prostatism - diagnosis Prostatism - drug therapy Prostatism - surgery Severity of Illness Index Sodium Potassium Chloride Symporter Inhibitors - adverse effects Sodium Potassium Chloride Symporter Inhibitors - therapeutic use Urinary Retention - chemically induced |
title | Pharmacological treatment of lower urinary tract symptoms in men: implementation of recommendations in clinical practice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T10%3A52%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacological%20treatment%20of%20lower%20urinary%20tract%20symptoms%20in%20men:%20implementation%20of%20recommendations%20in%20clinical%20practice&rft.jtitle=Actas%20urologicas%20espa%C3%B1olas&rft.au=Esteban,%20M&rft.aucorp=comit%C3%A9%20cient%C3%ADfico&rft.date=2013-06&rft.volume=37&rft.issue=6&rft.spage=330&rft.epage=337&rft.pages=330-337&rft.eissn=1699-7980&rft_id=info:doi/10.1016/j.acuro.2012.05.007&rft_dat=%3Cproquest_pubme%3E1445912824%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1445912824&rft_id=info:pmid/22959516&rfr_iscdi=true |